Stock reports › US › Healthcare

AbbVie Inc. (ABBV) stock analysis

AbbVie sits 1.70% below its record high with earnings due Oct 30 and options pricing a roughly 5% move

AbbVie closed at 286.44 on Oct 27, 2026, 1.70% below its 52-week and all-time high of 291.40, after a 44.89% six-month gain. Earnings are confirmed for Oct 30, with a forward P/E of 17.45 and a consensus mean target of 302.38. Debt, a payout ratio above 100% and a stretched technical picture are the main offsets.

  • Price: 286.44
  • Market Cap (USD): $507.28B
  • P/E: 80.34×
  • Fwd P/E: 17.45×
  • Div Yield: 2.42%
  • 1Y Return: 25.64%
  • Next Earnings: Oct 30, 2026
  • Mean Target: 302.38
  • Rating: Strong Buy

Bull case

  • Revenue grew 10.39% year over year to $64.39B on a trailing basis, and operating margin is 29.32%, in the 87th percentile of US healthcare, against a sector median of 15.06%.
  • The stock has strong momentum: price is 21.35% above its 200-day average of 236.05, the relative strength rating is 90, and the 50-day average crossed above the 200-day on Jul 9, 2026.
  • Analysts cite a mean target of 302.38 (5.56% above the price) from 16 analysts; Barclays raised its target to 325 on Oct 21 and Goldman Sachs to 294 on Oct 23, and consensus EPS growth for next year is 17.95%.

Bear case

  • Net debt is 64.25B, or 3.03× EBITDA, equity is negative at -5.93B and the current ratio is 0.81×, which limits balance sheet flexibility.
  • The payout ratio is 194.97% of trailing earnings against a 2.42% dividend yield, and free cash flow growth was -0.16% year over year.
  • The shares are extended after the run, with RSI at 65.6 and price 7.04% above the 50-day average. The last earnings reaction on Jul 31 was -4.78% despite a 1.11% EPS beat.

What to watch

  • Q3 earnings on Oct 30, 2026 (consensus EPS 3.73; options imply a 5.02% move).
  • The 52-week and all-time high of 291.40, set 8 days ago, and the 20-day low of 257.87.
  • The 20-day average at 277.27 and the 50-day average at 267.59 as trend support.
  • The next short interest update after the Oct 15 reading of 15.6M shares (0.88% of float).

General

AbbVie is a large biopharmaceutical company whose shares are near a record high ahead of earnings. Growth and margins are solid and the forward P/E is close to the sector median. Leverage and a high payout ratio are the main counterweights.

Business

The profile describes AbbVie as a global biopharmaceutical company that develops, makes and sells therapies including Humira, Skyrizi and Rinvoq. In fiscal 2025, Skyrizi was 30.19% of revenue ($17.56B) and Rinvoq 14.27% ($8.30B), while Humira was 7.80%. The United States was 95.17% of revenue.

Performance and valuation

Trailing revenue is $64.39B, up 10.39% year over year, with an operating margin of 29.32%. Forward P/E is 17.45 on next year's consensus EPS (16.41), against an industry median of 15.05 and a sector median of 17.62. Trailing P/E is 80.34 because earnings were depressed.

Market signals

Of the analyst ratings as of Oct 28, 31 are Buy, 12 Hold and 1 Sell. The mean target is 302.38. Short interest is low at 0.88% of float. The stock is up 25.36% year to date.

Long-term investor

Returns on capital and cash generation are strong, but the multi-year earnings record is distorted and leverage is high. Valuation is in line with peers on forward earnings, and estimates point to recovery.

Growth durability

Revenue rose from $54.32B in fiscal 2023 to $61.16B in fiscal 2025, though the 3-year revenue CAGR is only 1.75% and the 5-year is 5.95%. Diluted EPS was 2.37 in fiscal 2025 against 6.63 in fiscal 2022, a 3-year EPS CAGR of -29.03%. Quarterly revenue was $16.99B in Q2 FY2026.

Margins, returns and balance sheet

ROIC is 25.57%, in the 83rd percentile of peers, and free cash flow is $18.21B (28.28% margin). Debt is $70.82B against cash of $6.57B, interest coverage is 6.47×, and the Piotroski F-score is 8.

Capital return and valuation

The quarterly dividend is 1.73, up from 1.64 a year earlier, with 12 years of growth. Fiscal 2025 dividends were $11.66B against buybacks of $980.0M. Forward P/E of 17.45 is in the 48th percentile of the sector, and the PEG is 0.97×.

Swing trader

The trend is strongly up, with price above every major average and ADX at 33.89. The stock is near its high, though, and earnings on Oct 30 add event risk. Volume has been fading in recent sessions.

Trend and momentum

Price of 286.44 is above the 20-day (277.27), 50-day (267.59) and 200-day (236.05) averages. RSI is 65.6, the MACD of 6.32 is above its signal of 6.02, and stochastic K is 80.69. The relative strength rating is 90.

Levels and recent action

The 52-week high of 291.40 was set Oct 15, with a 20-day low of 257.87 and Bollinger bands at 258.53 and 296.01. The last 15 sessions have ranged roughly 282 to 291 since Oct 15. Oct 27 volume was 3.2M, or 0.67× average.

Risk and catalysts

ATR is 6.15 (2.15% of price). Earnings come Oct 30, and the last move was -4.78%. There were no upgrades or downgrades in 30 days, though several target raises. Short interest fell to 15.6M shares on Oct 15.

Options

Implied volatility is elevated against its own history and well above realized volatility, ahead of earnings. The term structure is inverted and liquidity is good.

Volatility level

30-day implied volatility is 31.80%, with a 52-week rank of 72 and percentile of 86 (range 20.62% to 36.15%). It is up 5.2 points over 20 days. Realized 30-day volatility is 17.93%, so implied is 1.77× realized, a premium that is rich.

Term structure and expected moves

The structure is backwardated: 30-day IV is 31.80% against 29.17% at 90 days, which is consistent with event pricing. Skew at 25 delta is -2.2 points. The 30-day expected move is 9.12% and the 7-day move is 4.40%.

Earnings and premium yields

The implied earnings move is 5.02%, against an 8-quarter average of 5.43% and a maximum of 8.25%, or 0.85× the average. The average IV crush is 6.62%. Annualized yield is 20.34% for the 30-delta cash-secured put and 16.73% for the covered call, with the earnings date before the Nov 27 expiry. Liquidity score is 88.

Analysis written October 28, 2026 from Qanvo data as of October 27, 2026. AI-generated, for information only; not investment advice.